Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis
- 1.3k Downloads
Previous observational studies have associated benzodiazepine use with an increased risk of dementia. However, limitations in the study methods leave questions unanswered regarding the interpretation of the findings.
A case–control analysis was conducted using data from the UK-based Clinical Practice Research Datalink (CPRD). A total of 26,459 patients aged ≥65 years with newly diagnosed Alzheimer’s disease (AD) or vascular dementia (VaD) between 1998 and 2013 were identified and matched 1:1 to dementia-free controls on age, sex, calendar time, general practice, and number of years of recorded history. Adjusted odds ratios (aORs) were calculated with 95 % confidence intervals (CIs) of developing AD or VaD in relation to previous benzodiazepine use, stratified by duration and benzodiazepine type.
The aOR (95 % CI) of developing AD for those who started benzodiazepines <1 year before diagnosis was 2.20 (1.91–2.53), and fell to the null for those who started between 2 and <3 years before [aOR 0.99 (0.84–1.17)]. The aOR (95 % CI) of developing VaD for those who started benzodiazepines <1 year before diagnosis was 3.30 (2.78–3.92), and fell close to the null for those who started between 3 and <4 years before [aOR 1.16 (0.96–1.40)]. After accounting for benzodiazepine use initiated during this prodromal phase, long-term use of benzodiazepines was not associated with an increased risk of developing AD [aOR 0.69 (0.57–0.85)] or VaD [aOR 1.11 (0.85–1.45)].
After taking a prodromal phase into consideration, benzodiazepine use was not associated with an increased risk of developing AD or VaD.
KeywordsDementia Zaleplon Induction Time Prodromal Symptom Diagnosis Date
The authors would like to thank Pascal Egger for programming and technical support.
Compliance with Ethical Standards
No funding was received for this study.
Conflicts of interest
Patrick Imfeld, Michael Bodmer, Susan S. Jick, and Christoph R. Meier declare that they have no conflicts of interest.
- 1.NHS Business Services Authority, NHS Prescription Services. Central nervous system national charts. 2014. Available at: http://www.nhsbsa.nhs.uk/PrescriptionServices/2584.aspx. Accessed 26 Apr 2015.
- 21.Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3:e002080.PubMedCentralCrossRefPubMedGoogle Scholar